Taysha Gene Therapies
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $2,022 | $1,788 | $1,112 | $3,411 |
Gross Profit | 2,647 | 1,788 | 812 | 3,086 |
EBITDA | -18,443 | -25,200 | -20,601 | -23,707 |
EBIT | -18,769 | -25,494 | -20,901 | -24,032 |
Net Income | -18,785 | -25,524 | -20,928 | -24,061 |
Net Change In Cash | 2,022 | 1,788 | 1,112 | 3,411 |
Free Cash Flow | -18,306 | -21,650 | -21,705 | -19,956 |
Cash | 139,036 | 157,688 | 172,743 | 124,429 |
Basic Shares | 250,134 | 267,824 | 232,821 | 231,249 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $8,333 | $15,451 | $2,502 | $0 |
Gross Profit | 8,333 | 15,451 | 15 | -492 |
EBITDA | -87,951 | -105,197 | -159,729 | -172,775 |
EBIT | -89,196 | -106,568 | -162,216 | -173,267 |
Net Income | -89,298 | -111,566 | -169,581 | -175,459 |
Net Change In Cash | 8,333 | 15,451 | 2,502 | 0 |
Free Cash Flow | -81,599 | -80,387 | -113,259 | -138,596 |
Cash | 139,036 | 143,940 | 87,880 | 149,103 |
Basic Shares | 250,134 | 232,242 | 175,808 | 150,602 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.07 |
2024-09-30 | -$0.07 |
2024-06-30 | -$0.09 |
2024-03-31 | -$0.10 |
